NueHealth has entered a three-year partnership agreement with GeneNews — a Canadian diagnostic products company — to offer its patients early cancer detection tests.
Here's what you need to know:
1. Patients of NueHealth's provider networks will have access to three screening types, including ColonSentry, a screening test that provides early risk stratification for colorectal cancer.
2. ColonSentry utilizes a blood test, which measures the expression of gene biomarkers that are early warning signs of colorectal cancer.
3. The tests will be processed by GeneNews at a clinical reference lab in Richmond, Va.